Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 9/20 | 0.45 |
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594873 | 0.90 | PIM1 (0.45) | RETPIM1FYNPIM2KDR | |
| SCHEMBL4695824 | 0.90 | PIM1 (0.43) | RETPIM1FYNPIM2KDR | |
| SCHEMBL4595639 | 0.89 | PIM1 (0.60) | RETPIM1FYNPIM2 | |
| SCHEMBL4594268 | 0.89 | FYN (0.58) | RETPIM1FYNPIM2 | |
| SCHEMBL4331906 | 0.88 | FYN (0.46) | RETPIM1FYNPIM2KCNA5 | |
| SCHEMBL4338189 | 0.88 | PIM1 (0.51) | PIM1FYNPIM2KCNA5KDR | |
| SCHEMBL4595026 | 0.87 | FYN (0.49) | RETPIM1FYNKDR | |
| SCHEMBL4594475 | 0.85 | CHEK1 (0.45) | RETPIM1FYN | |
| SCHEMBL4594795 | 0.85 | PIM1 (0.44) | RETPIM1FYNPIM2 | |
| SCHEMBL4333059 | 0.85 | PIM1 (0.39) | RETPIM1FYNPIM2KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049539-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | claimed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | claimed |
| WO-2007147647-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME. | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | DPYD, FLT1, PDXK | RET 911/4885PIM1 400/4885FYN 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.